Cargando…

Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes

Neuroendocrine tumors (NETs) are rare cancers with an associated prolonged survival in some patients. A proportion of patients diagnosed with NETs will present with carcinoid syndrome symptoms, characterized by diarrhea, flushing and/or wheezing. This review summarizes the current treatment options...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saavedra, Cristina, Barriuso, Jorge, McNamara, Mairéad G, Valle, Juan W, Lamarca, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690650/ https://www.ncbi.nlm.nih.gov/pubmed/31496810 http://dx.doi.org/10.2147/CMAR.S181439

Ejemplares similares

Telotristat ethyl for carcinoid syndrome diarrhoea
Publicado: (2019)

Survival and Clinical Outcomes with Telotristat Ethyl in Patients with Carcinoid Syndrome
por: Metz, David C, et al.
Publicado: (2020)

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial
por: Pavel, Marianne, et al.
Publicado: (2018)

In Reply: Telotristat Ethyl for Patients With Carcinoid Syndrome Associated With Chest Pain and Hypertension
por: Jiang, Wenjun, et al.
Publicado: (2018)

Developments in the treatment of carcinoid syndrome – impact of telotristat
por: Chan, David L, et al.
Publicado: (2018)

TELEPRO: Patient‐Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World
por: Strosberg, Jonathan, et al.
Publicado: (2019)

Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome
por: Dillon, Joseph S., et al.
Publicado: (2020)

Changes in Carcinoid Syndrome Symptoms Among Patients Receiving Telotristat Ethyl in US Clinical Practice: Findings from the TELEPRO-II Real-World Study
por: Kulke, Matthew H, et al.
Publicado: (2021)

Telotristat ethyl reverses myxomatous changes in mice mitral valves
por: Wang, Xinmei, et al.
Publicado: (2022)

Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)
por: Megdanova-Chipeva, Vera G., et al.
Publicado: (2020)

Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice
por: Lamarca, Angela, et al.
Publicado: (2022)

Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review
por: Shotton, Rohan, et al.
Publicado: (2021)

Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach
por: Gelhorn, Heather L., et al.
Publicado: (2016)

The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms
por: Shah, Dinakshi, et al.
Publicado: (2021)

Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice
por: Lamarca, Angela, et al.
Publicado: (2019)

Antiproliferative Effects of Telotristat Ethyl in Patients with Neuroendocrine Tumors: The TELEACE Real-World Chart Review Study
por: Morse, Michael A, et al.
Publicado: (2020)

Management of Diarrhea in Patients With Carcinoid Syndrome
por: Naraev, Boris G., et al.
Publicado: (2019)

The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
por: Lamarca, Angela, et al.
Publicado: (2018)

The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer
por: Abdul Rahman, Rozana, et al.
Publicado: (2021)

Real-World Clinical and Patient-Reported Outcomes from the Longitudinal Telotristat Ethyl Treatment Registry of Patients with Neuroendocrine Tumors
por: Li, Daneng, et al.
Publicado: (2022)

Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
por: Foy, Victoria, et al.
Publicado: (2023)

Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment (PanDA): a study protocol
por: Carnie, Lindsay E, et al.
Publicado: (2021)

PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours
por: Lamarca, Angela, et al.
Publicado: (2018)

Optimizing the Management of Carcinoid Syndrome to Reduce the Impact of Diarrhea
por: Randall, Rory, et al.
Publicado: (2019)

The journey from gene knockout to clinical medicine: telotristat and sotagliflozin
por: Rendell, Marc S
Publicado: (2019)

Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis
por: McNamara, Mairéad G., et al.
Publicado: (2020)

Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis
por: Frizziero, Melissa, et al.
Publicado: (2020)

Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea
por: Fragkos, Konstantinos C
Publicado: (2017)

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
por: Galdy, Salvatore, et al.
Publicado: (2016)

Targeted Therapies for Perihilar Cholangiocarcinoma
por: Gray, Simon, et al.
Publicado: (2022)

Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy (PANcreatic Cancer Dietary Assessment—PanDA)
por: Carnie, Lindsay E., et al.
Publicado: (2023)

Direct costs of carcinoid syndrome diarrhea among adults in the United States
por: Dasari, Arvind, et al.
Publicado: (2019)

Urine Telomerase for Diagnosis and Surveillance of Bladder Cancer
por: Lamarca, Angela, et al.
Publicado: (2012)

Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes
por: Taboada, Rodrigo G, et al.
Publicado: (2022)

Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer
por: Pihlak, Rille, et al.
Publicado: (2023)

New Developments in the Treatment of Neuroendocrine Tumours – RADIANT-4, NETTER-1 and Telotristat Etiprate
por: Sbardella, Emilia, et al.
Publicado: (2016)

Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma
por: Weaver, Jamie M. J., et al.
Publicado: (2023)

Rectal Mechano-sensory Function in Patients with Carcinoid Diarrhea
por: Gregersen, Tine, et al.
Publicado: (2016)

Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma
por: Najran, Pavan, et al.
Publicado: (2017)

Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers
por: Lamarca, Angela, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_93se3u2ihcan6i648thi9im1ro